【产品介绍】：

生物活性：Atazanavir-d5 is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration[1]. Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp)[2]. Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM[3].
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Atazanavir-d5 相关抗体:
BNSP Antibody
FACL4 Antibody
BrdU Antibody (YA578)
GAPDH Antibody
Glucose 6 Phosphate Dehydrogenase Antibody
Cytochrome C Antibody
METTL3 Antibody
TSG101 Antibody
Alkaline Phosphatase Antibody
Calnexin Antibody (YA573)
CD4 Antibody
Lamin A/C Antibody
Lamin B1 Antibody
LAMP1 Antibody
LAMP2 Antibody (YA713)
LAMP2a Antibody
NQO1 Antibody (YA697)
NQO1 Antibody (YA261)
OPA1 Antibody
RBM3 Antibody
Synaptophysin Antibody (YA043)
Laminin beta 1 Antibody
Cytochrome P450 17A1 Antibody
Heme Oxygenase 1 Antibody
Ki67 Antibody (YA717)
Ki67 Antibody (YA322)
Aromatase Antibody
Asparagine Synthetase Antibody
Calnexin Antibody
Ki67 Antibody (YA001)
分子量：709.89
Formula：C38H47D5N6O7
CAS 号：1132747-14-8
非标记 CAS：198904-31-3
中文名称：阿扎那韦-d5
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (537 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[2]. Wood R. Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther. 2008 Dec;6(6):785-96.
 [Content Brief]
[3]. Havlir DV, et al. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis. 2004 Jun 1;38(11):1599-604.
 [Content Brief]
[4]. Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.
 [Content Brief]